{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Korro Bio, Inc."},"Symbol":{"label":"Symbol","value":"KRRO"},"Address":{"label":"Address","value":"75 HAYDEN AVENUE,SUITE 300, LEXINGTON, Massachusetts, 02421, United States"},"Phone":{"label":"Phone","value":"+1 866 389-1970"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss."},"CompanyUrl":{"label":"Company Url","value":"https://www.korrobio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Kemi Olugemo","title":"Chief Medical Officer"},{"name":"Ram Aiyar","title":"President, Chief Executive Officer & Director"},{"name":"Todd Chappell","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}